OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press53610.17650/1818-8346-2022-17-2-36-42RARE AND COMPLEX CLINICAL SITUATIONS: DIAGNOSTIC DIFFICULTIE AND TREATMENT CHOICEРЕДКИЕ И СЛОЖНЫЕ КЛИНИЧЕСКИЕ СИТУАЦИИ: ТРУДНОСТИ ДИАГНОСТИКИ И ВЫБОР ТАКТИКИ ЛЕЧЕНИЯA rare case of an anaphylactic reaction to plasma and recombinant blood coagulation factor VIII in a child with severe hemophilia AРедкий случай анафилактической реакции на введение плазменного и рекомбинантного фактора свертывания крови VIII у ребенка с тяжелой формой гемофилии Аhttps://orcid.org/0000-0002-2738-429XDmitrievV. V.ДмитриевВ. В.
Belarus

223053, Minsk region, Borovlyany, Frunzenskaya St., 43

223053 Минский район, д. Боровляны, ул. Фрунзенская, 43

dmitrievhaematol@mail.ruNaumovichM. G.НаумовичМ. Г.
Belarus

223053, Minsk region, Borovlyany, Frunzenskaya St., 43

223053 Минский район, д. Боровляны, ул. Фрунзенская, 43

https://orcid.org/0000-0003-0233-7718DmitrievE. V.ДмитриевЕ. В.
Belarus

223053, Minsk region, Borovlyany, Frunzenskaya St., 43

223053 Минский район, д. Боровляны, ул. Фрунзенская, 43

Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyГУ «Республиканский научно-практический центр детской онкологии, гематологии и иммунологии» Минздрава Республики Беларусь1404202217236421204202212042022https://oncohematology.abvpress.ru/ongm/article/view/536

A rare case of anaphylactic shock after administration of 4th generation recombinant blood coagulation factor VIII is presented. Anaphylactic shock is a life-threatening complication for a patient with hemophilia A. Temporarily refrain from re-administration of factor VIII, a skin test confirming drug choice, and a patient desensitization procedure provide the clinician with a chance to continue hemostatic replacement therapy for a patient with hemophilia A.The main purpose of this case report is to determine the algorithm of actions to overcome the consequences of anaphylactic shock and continue the prophylactic administration of coagulation factor VIII concentrate to prevent bleeding in a child with a rare random combination of an anaphylactic reaction and congenital coagulation disorders.

Представлен редкий случай анафилактического шока на введение лекарственного средства, содержащего рекомбинантный фактор свертывания крови VIII 4-го поколения. Анафилактический шок представляет серьезную опасность для жизни пациента с гемофилией А. Временное воздержание от повторного введения фактора свертывания VIII, кожная проба, подтверждающая возможность выбора лекарственного средства, и процедура десенсибилизации пациента предоставляют врачу шанс продолжения заместительной гемостатической терапии у пациента с гемофилией А.Основная цель наблюдения заключается в определении порядка действий по преодолению последствий анафилактического шока и продолжения профилактического введения концентрата фактора свертывания крови VIII для предупреждения кровотечений у ребенка с редким случайным сочетанием анафилактической реакции и врожденных нарушений свертывания крови.

childrensevere form of hemophilia Ahemostatic replacement therapyanaphylactic reactionpathological clotting inhibitorдетитяжелая форма гемофилии Азаместительная гемостатическая терапияанафилактическая реакцияпатологический ингибитор свертывания1. Eyster M.E., Bowman H.S., Haverstick J.N. Adverse reactions to factor VIII infusions. Ann Intern Med 1977;87(2):248. DOI:10.7326/0003-4819-87-2-248_1.Eyster M.E., Bowman H.S., Haverstick J.N. Adverse reactions to factor VIII infusions. Ann Intern Med 1977;87(2):248. DOI:10.7326/0003-4819-87-2-248_1.2. Ahrons S., Glavind-Kristensen S., Drachmann O., Kissmeyer-Nielsen F. Severe reactions after cryoprecipitated human factor VIII. Vox Sang 1970;18(2):182–4. DOI:10.1111/j.1423-0410.1970.tb01445.x.Ahrons S., Glavind-Kristensen S., Drachmann O., Kissmeyer-Nielsen F. Severe reactions after cryoprecipitated human factor VIII. Vox Sang 1970;18(2):182–4. DOI:10.1111/j.1423-0410.1970.tb01445.x.3. Clapp R., Green D. Reaction to rapidly infused AHF cryoprecipitate. N Engl J Med 1969;281(6):329. DOI:10.1056/NEJM196908072810617.Clapp R., Green D. Reaction to rapidly infused AHF cryoprecipitate. N Engl J Med 1969;281(6):329. DOI:10.1056/NEJM196908072810617.4. Eisen V. Studies of fibrinogen fractions isolated from human plasma by precipitation with cold ether. II. Enzymic activities resembling plasma kallikrein and C’I-esterase. Br J Haematol 1965;11(5):576–85. DOI:10.1111/j.1365-2141.1965.tb00102.x.Eisen V. Studies of fibrinogen fractions isolated from human plasma by precipitation with cold ether. II. Enzymic activities resembling plasma kallikrein and C’I-esterase. Br J Haematol 1965;11(5):576–85. DOI:10.1111/j.1365-2141.1965.tb00102.x.5. Montalvão S.A.L., Tucunduva A., Siqueira L.H. et al. Allergic reaction in a cohort of haemophilia A patientsusing plasma-derived factor VIII (FVIII) concentrate is rareand not necessarily triggered by FVIII. Haemophilia 2015; 21(4):e281–5. DOI:10.1111/hae.12647.Montalvão S.A.L., Tucunduva A., Siqueira L.H. et al. Allergic reaction in a cohort of haemophilia A patientsusing plasma-derived factor VIII (FVIII) concentrate is rareand not necessarily triggered by FVIII. Haemophilia 2015; 21(4):e281–5. DOI:10.1111/hae.12647.6. Pernod G., Armari C., Barro C. et al. Anaphylaxis following the use of a plasmaderived immunopurified monoclate-P, and the recombinant Recombinate and Kogenate factor VIII: a therapeutic challenge. Haemophilia 1999;5(2):143–4.Pernod G., Armari C., Barro C. et al. Anaphylaxis following the use of a plasmaderived immunopurified monoclate-P, and the recombinant Recombinate and Kogenate factor VIII: a therapeutic challenge. Haemophilia 1999;5(2):143–4.7. Franchini M., Lippi G. Recombinant factor VIII concentrates. Semin Thromb Hemost 2010;36(5):493–7. DOI:10.1055/s-0030-1255443.Franchini M., Lippi G. Recombinant factor VIII concentrates. Semin Thromb Hemost 2010;36(5):493–7. DOI:10.1055/s-0030-1255443.8. Kadar J., Schuster J., Hunzelmann N. IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A. Haemophilia 2007;13(1):104–5. DOI:10.1111/j.1365-2516.2006.01339.x.Kadar J., Schuster J., Hunzelmann N. IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A. Haemophilia 2007;13(1):104–5. DOI:10.1111/j.1365-2516.2006.01339.x.9. Pires S., Sevivas T., Chaves Loureiro C. et al. Anaphylaxis after treatment with recombinant factor VIII: investigation and therapeutic challenge. BMJ Case Rep 2018;11(1):e227426. DOI:10.1136/bcr-2018-227426.Pires S., Sevivas T., Chaves Loureiro C. et al. Anaphylaxis after treatment with recombinant factor VIII: investigation and therapeutic challenge. BMJ Case Rep 2018;11(1):e227426. DOI:10.1136/bcr-2018-227426.10. Platt C.D., D’Angelo L., Neufeld E.J., Dioun Broyles A. Skin testing, graded challenge, and desensitization to von Willebrand factor (VWF) products in type III vonWillebrand disease (VWD). J Allergy Clin Immunol Pract 2016;4(5):1006–8. DOI:10.1016/j.jaip.2016.05.017.Platt C.D., D’Angelo L., Neufeld E.J., Dioun Broyles A. Skin testing, graded challenge, and desensitization to von Willebrand factor (VWF) products in type III vonWillebrand disease (VWD). J Allergy Clin Immunol Pract 2016;4(5):1006–8. DOI:10.1016/j.jaip.2016.05.017.11. Beken В., Celik V., Ozdemir P.G. et al. Successful desensitization of a patient with possible IgE-mediated anaphylactic reaction to FVIII/VWF concentrate. Pediatr Allergy Immunol Рulmonol 2019;32(2): 81–4. DOI:10.1089/ped.2018.0969.Beken В., Celik V., Ozdemir P.G. et al. Successful desensitization of a patient with possible IgE-mediated anaphylactic reaction to FVIII/VWF concentrate. Pediatr Allergy Immunol Рulmonol 2019;32(2): 81–4. DOI:10.1089/ped.2018.0969.12. Levy-Mendelovicha S., Livnata T., Barg A.A. et al. Allergy and inhibitors in hemophilia – a rare complication with potentialnovel solutions. Blood Cells Mol Dis 2020;80:102370. DOI:10.1016/j.bcmd.2019.102370.Levy-Mendelovicha S., Livnata T., Barg A.A. et al. Allergy and inhibitors in hemophilia – a rare complication with potentialnovel solutions. Blood Cells Mol Dis 2020;80:102370. DOI:10.1016/j.bcmd.2019.102370.13. Cugno M., Mancuso M.E., Tedeschi A. et al. Involvement of the IgE-basophil system and mildcomplement activation in haemophilia B with anti-factor IX neutralizingantibodies and anaphylaxis. Haemophilia 2017;23(4):e348–53. DOI:10.1111/hae.13282.Cugno M., Mancuso M.E., Tedeschi A. et al. Involvement of the IgE-basophil system and mildcomplement activation in haemophilia B with anti-factor IX neutralizingantibodies and anaphylaxis. Haemophilia 2017;23(4):e348–53. DOI:10.1111/hae.13282.14. Sandberg H., Kannicht C., Stenlund P. et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res 2012;130(5):808–17. DOI:10.1016/j.thromres.2012.08.311.Sandberg H., Kannicht C., Stenlund P. et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res 2012;130(5):808–17. DOI:10.1016/j.thromres.2012.08.311.15. Behrmann M., Pasi J., Saint-Remy J.M.R. et al. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002;88(2):221–9.Behrmann M., Pasi J., Saint-Remy J.M.R. et al. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002;88(2):221–9.16. Gensana M., Altisent C., Aznar J.A. et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001;7(4):369–74. DOI:10.1046/j.1365-2516.2001.00526.x.Gensana M., Altisent C., Aznar J.A. et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001;7(4):369–74. DOI:10.1046/j.1365-2516.2001.00526.x.17. Verbruggen B., Novakova I., Wessels H. et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73(2):247–51.Verbruggen B., Novakova I., Wessels H. et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73(2):247–51.